BioCryst Pharmaceuticals
BioCryst Pharmaceuticals
Explore linked clinical trials.3 results ยท Page 1 of 1
Clinical trials
Swipe the table sideways for more columns.
| Trial | Conditions | Status | Phase | Updated | More info | NCT ID |
|---|---|---|---|---|---|---|
| A Study of the Safety, Tolerability, Pharmacokinetics, and Immunogenicity of BCX17725 | Abnormalities, Multiple, Congenital Abnormalities, Congenital, Hereditary, and Neonatal Diseases and Abnormalities, Ichthyosiform Erythroderma, Congenital, Infant, Newborn, Diseases, Netherton syndrome, Skin Abnormalities, Skin and Connective Tissue Diseases, hereditary disease, hereditary skin disorder, ichthyosis, keratosis, skin disorder | Recruiting | Phase 1 | 2026-08-27 | NCT06539507 | |
| Berotralstat Treatment in Children With Hereditary Angioedema | Congenital, Hereditary, and Neonatal Diseases and Abnormalities, Hereditary Complement Deficiency Diseases, Hypersensitivity, Immediate, Primary Immunodeficiency Diseases, Skin and Connective Tissue Diseases, angioedema, cardiovascular disorder, hereditary angioedema, hereditary disease, immune system disorder, inborn error of immunity, skin disorder, skin vascular disease, urticaria, vascular disorder | Active, not recruiting | Phase 3 | 2026-02-25 | NCT05453968 | |
| Open-label Berotralstat Access to HAE Patients Previously Enrolled in Berotralstat Studies | Congenital, Hereditary, and Neonatal Diseases and Abnormalities, Hereditary Complement Deficiency Diseases, Hypersensitivity, Immediate, Primary Immunodeficiency Diseases, Skin and Connective Tissue Diseases, angioedema, cardiovascular disorder, hereditary angioedema, hereditary disease, immune system disorder, inborn error of immunity, skin disorder, skin vascular disease, urticaria, vascular disorder | Enrolling by invitation | Phase 3 | 2025-12-23 | NCT04933721 |